Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07182227 · ClinicalTrials.gov registry record · Phase 1
PS-002 for the Treatment of IgA Nephropathy in Adults
A Phase 1 study of Immunoglobulin A (IgA) Nephropathy, sponsored by Purespring Therapeutics Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 11
- Study locations
NCT07182227 is a Phase 1 study of Immunoglobulin A (IgA) Nephropathy that is actively recruiting participants, run by Purespring Therapeutics Limited. The registered enrollment target is 32 participants. The trial reports 11 study locations across 7 states.
The verdict
NCT07182227, a Phase 1 study of Immunoglobulin A (IgA) Nephropathy, is actively recruiting participants, sponsored by Purespring Therapeutics Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary Immunoglobulin A (IgA) nephropathy. This will be a first-in-human study and will include participants at high risk of disease progression despite receiving current standard-of-care treatment. Participants will be monitored for up to one year after receiving PS-002 and invited to take part in a long-term follow-up study (total follow-up: 5 years).
Conditions Studied
Interventions
- GENETIC PS-002
Study Locations (11)
Other
- Southmead Hospital - Bristol
- Cardiff and Vale University Health Board - Cardiff
- Royal Infirmary of Edinburgh Clinical Research Facility - Edinburgh
- The Royal London Hospital - London
Greater Manchester
- Manchester University NHS Foundation Trust - Manchester
- Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust - Manchester
Florida
- University of Miami Hospital - Miami
Maryland
- The Johns Hopkins Hospital - Baltimore
Michigan
- University of Michigan Hospital - Ann Arbor
Leicestershire
- Leicester General Hospital - Leicester
Nottinghamshire
- Nottingham University Hospitals NHS Trust - Nottingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-02 |
| Est. Completion | 2029-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07182227
The ClinicalTrials.gov registry entry for NCT07182227 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purespring Therapeutics Limited, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Immunoglobulin A (IgA) Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which PS-002 is the first listed.
NCT07182227 reports 11 study locations spanning 7 distinct geographic areas - top geographies include Other, Greater Manchester, Florida.
Frequently Asked Questions
What is clinical trial NCT07182227 about?
NCT07182227 is a clinical study titled "PS-002 for the Treatment of IgA Nephropathy in Adults". The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary Immunoglobulin A (IgA) nephropathy. This will be a first-in-human study and will include participants at high risk of disease progression despite rece...
What is the current status of trial NCT07182227?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-02. Estimated completion is 2029-09.
What conditions does trial NCT07182227 study?
This clinical trial studies the following conditions: Immunoglobulin A (IgA) Nephropathy.
What interventions are being tested in trial NCT07182227?
The interventions under investigation include: PS-002 (GENETIC).
Who is sponsoring clinical trial NCT07182227?
This trial is sponsored by Purespring Therapeutics Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07182227 being conducted?
This trial has 11 study locations across Florida, Maryland, Michigan, Greater Manchester, Leicestershire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunoglobulin A (IgA) Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.